东方证券承销保荐有限公司 关于上海三友医疗器械股份有限公司 首次公开发行股票并在科创板上市之 保荐总结报告书 经中国证券监督管理委员会证监许可【2020】402 号文《关于同意上海三友 医疗器械股份有限公司首次公开发行股票注册的批复》，上海三友医疗器械股份 有限公司（以下简称"三友医疗"或"公司"）首次公开发行的股票于 2020 年 4 月 9 日在上海证券交易所上市。东方证券承销保荐有限公司（以下简称"东方投 行"或"保荐机构"）作为三友医疗首次公开发行股票并上市持续督导的保荐机 构，负责三友医疗上市后的持续督导工作，持续督导期间自 2020 年 4 月 9 日至 2023 年 12 月 31 日。 截至 2023 年 12 月 31 日，三友医疗持续督导期已届满，东方投行根据《证 券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》《上海证 券交易所科创板上市公司自律监管规则适用指引第 1 号——规范运作》等法规、 规范性文件相关要求，出具本保荐总结报告书。 一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导性陈 述或重大遗漏，保荐机构及保荐代表人 ...

( ) DaHua Certified Public Accountants Special General Partnership SHIFT 2023 12 31 [2024]0011000266 F9 1-2 2023 1 16 7 12 [100039] 86 (10) 5835 0011 86 (10) 5835 0006 [2024]0011000266 2023 2023 12 31 2023 2024 4 24 2024 0011002841 7 2023 2023 2023 2023 1 大华核字[2024]0011000266 号关联方资金占用情况的专项说明 易所的要求出具的,不得用作其他用途。由于使用不当所造成的后果, 与执行本业务的注册会计师和会计师事务所无关。 附件: 上海三友医疗器械股份有限公司 2023 年度非经营性资金 占用及其他关联资金往来情况汇总表 大华会计师 普通合伙） 中国注册会计师: 张俊峰 张世盛 二〇二四年四月二十四日 中国注册会计师: | 444.15 | 1,522.06 | 9,135.79 | 2.02 | 203.29 | 345.73 | | | | ...

Financial Performance - The company's operating revenue for 2023 was ¥460,392,060.81, a decrease of 29.08% compared to ¥649,152,314.95 in 2022[20]. - The net profit attributable to shareholders for 2023 was ¥95,582,882.73, down 49.91% from ¥190,818,290.90 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥59,284,633.82, a decline of 55.70% from ¥133,822,488.60 in 2022[20]. - Basic earnings per share decreased by 50.65% to CNY 0.38 in 2023 compared to CNY 0.77 in 2022[21]. - The weighted average return on equity fell by 5.75 percentage points to 5.09% in 2023 from 10.84% in 2022[21]. - The company reported a total revenue of 29,248.97 million RMB for the period, with a net profit of 22,385.74 million RMB, indicating a strong financial performance[131]. - The net profit attributable to shareholders was 95.58 million RMB, down 49.91% year-on-year, primarily due to significant price reductions in spinal products following the implementation of national volume-based procurement policies[147]. Cash Flow and Assets - The net cash flow from operating activities increased by 71.46% to ¥267,433,845.71 in 2023, compared to ¥155,972,694.91 in 2022[20]. - As of the end of 2023, the net assets attributable to shareholders were ¥1,916,191,204.13, an increase of 4.16% from ¥1,839,743,607.05 at the end of 2022[20]. - Total assets at the end of 2023 were ¥2,261,496,123.25, reflecting a 3.20% increase from ¥2,191,365,967.39 in 2022[20]. - The company's accounts receivable net amount was 61.52 million yuan, a decrease of 213.84 million yuan, representing a decline of 77.66%[153]. - The company's inventory book value was 176.66 million yuan, an increase of 21.58 million yuan, reflecting a growth of 13.91%[154]. - The company's cash and cash equivalents increased by 314 million yuan, reaching 65,435.26 million yuan, primarily due to the maturity of cash management products from the previous year[189]. Research and Development - Research and development expenditure as a percentage of operating revenue increased by 4.87 percentage points to 14.17% in 2023 from 9.30% in 2022[21]. - The company achieved a total R&D investment of ¥65.22 million in 2023, representing an increase of 8.02% compared to ¥60.38 million in the previous year[122]. - The number of R&D personnel increased to 100, representing 21.46% of the total workforce, up from 19.82% in the previous period[134]. - The company has established a comprehensive project evaluation and R&D system, with a CNAS-accredited laboratory for orthopedic implant testing[140]. - The core R&D team includes experts with advanced degrees from prestigious universities, contributing to the development of key products such as the Adena spinal system and Halis PEEK interbody fusion device[84]. Market and Product Development - The company is actively investing in high-end medical device technology and expanding into overseas high-end markets[31]. - The company is focused on developing orthopedic implants and ultrasonic power devices, with ongoing projects targeting pediatric spinal deformities and minimally invasive surgical techniques[56]. - The company is expanding its product line with innovative designs that cater to a wide range of clinical needs, enhancing overall surgical outcomes[68]. - The company is actively involved in clinical research collaborations with medical institutions to better understand clinical needs and pain points[97]. - The company is focusing on breaking the monopoly of foreign manufacturers in high-end medical devices, particularly in the field of large-diameter vessel closure technology[131]. Compliance and Governance - The company has received a standard unqualified audit report from Da Hua Certified Public Accountants[4]. - The board of directors has confirmed the authenticity and completeness of the annual report[3]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[7]. - There are no violations of decision-making procedures for external guarantees[8]. - The company emphasizes that forward-looking statements do not constitute substantive commitments to investors[6]. Strategic Investments and Acquisitions - The company acquired a controlling stake of 60% in Tuoteng Huabao and 55% in Youhe Jicheng, which were included in the consolidation scope in June and December 2023, respectively[178]. - The company invested 25 million yuan in Jiaoying Medical Devices (Shanghai) Co., Ltd., acquiring a 13.8421% stake, and 13.0658 million yuan in Guangzhou Ruitai Biotechnology Co., Ltd., acquiring a 1.4268% stake[193]. - The company plans to acquire 55% of Youhe Jicheng Medical Technology Co., Ltd. for 30.53 million yuan, with the investment already completed[194]. - The company increased its stake in Implanet from 41.03% to 74.56% by investing 500,000 euros, making it a controlling company[195]. Risk Management - The management has outlined potential risks in the production and operation processes, which investors are advised to review[3]. - The company faces risks related to new product development failures and potential core technology leaks, which could adversely affect its operations[149][150]. Employee and Organizational Development - The company has implemented a dual-channel talent development strategy, enhancing employee skills and core competencies through customized training programs[55]. - The company received the αi Excellent Workplace Award for three consecutive years, reflecting its commitment to employee satisfaction and organizational effectiveness[55]. - The company has established a digital platform for human resource management, improving management efficiency and data security[55].

证券代码：688085 证券简称：三友医疗 公告编号：2024-017 上海三友医疗器械股份有限公司 关于制定和修订部分公司治理制度 及调整第三届董事会审计委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海三友医疗器械股份有限公司（以下简称"三友医疗"或"公司"）于 2024 年 4 月 24 日召开第三届董事会第十次会议，审议通过了《关于调整董事 会审计委员会委员的议案》及《关于制定部分公司治理制度的议案》、《关于修 订部分公司治理制度的议案》，具体情况如下： | 序号 | 制度名称 | 变更情况 | 是否需要提交 | | --- | --- | --- | --- | | | | | 股东大会审议 | | 1 | 《上海三友医疗器械股份有限公司独立 董事专门会议工作细则》 | 制定 | 否 | | 2 | 《上海三友医疗器械股份有限公司年报 | 制定 | 否 | | | 信息披露重大差错责任追究制度》 | | | | --- | --- | --- | --- | | 3 | 《上海三友医疗器械股份 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥86,429,306.35, representing a decrease of 46.26% compared to the same period last year[6]. - The net profit attributable to shareholders was -¥2,095,834.44, a decline of 106.05% year-on-year[6]. - The net cash flow from operating activities was -¥49,593,677.75, reflecting a decrease of 223.89% compared to the previous year[6]. - Total operating revenue for Q1 2024 was ¥86,429,306.35, a decrease of 46.3% compared to ¥160,838,817.82 in Q1 2023[24]. - Net profit for Q1 2024 was a loss of ¥3,865,487.47, compared to a profit of ¥35,107,002.53 in Q1 2023, representing a significant decline[25]. - Total comprehensive income for Q1 2024 was a loss of ¥10,000,793.53, compared to a profit of ¥35,107,002.53 in Q1 2023[26]. - The company's total revenue for Q1 2024 was CNY 62,411,718.98, a decrease of 58.2% compared to CNY 149,243,093.98 in Q1 2023[33]. - The net profit for Q1 2024 was CNY 5,612,045.01, down 85.2% from CNY 37,855,113.88 in Q1 2023[34]. Cash Flow and Liquidity - As of March 31, 2024, the company's cash and cash equivalents amounted to ¥610,099,287.41, a decrease from ¥654,352,614.54 as of December 31, 2023[20]. - Cash and cash equivalents at the end of Q1 2024 were CNY 610,099,287.41, compared to CNY 568,187,842.74 at the end of 2023, reflecting a 7.5% increase[29]. - The company experienced a cash decrease of 59,910,300.70 RMB in Q1 2024, contrasting with an increase of 216,355,931.50 RMB in Q1 2023[38]. - The cash inflow from sales of goods and services was 65,130,414.66 RMB, down from 147,503,580.28 RMB year-over-year, indicating a decline of approximately 55.8%[36]. - The net cash flow from operating activities for Q1 2024 is not provided in the available data, indicating a need for further analysis[35]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,316,290,516.28, a 2.42% increase from the previous year[7]. - The company's total assets as of March 31, 2024, were CNY 2,081,497,782.29, slightly down from CNY 2,083,132,157.99 at the end of 2023[32]. - The total liabilities decreased to CNY 178,399,011.18 in Q1 2024 from CNY 185,645,431.89 at the end of 2023, a reduction of 3.4%[32]. - The company's total liabilities increased to ¥266,421,144.01 from ¥218,795,986.78, representing a rise of about 21.8%[22]. - Total equity attributable to shareholders was ¥1,915,574,889.81, slightly down from ¥1,916,191,204.13[22]. Research and Development - Research and development expenses totaled ¥17,260,292.96, which is an increase of 20.96% year-on-year, accounting for 19.97% of operating revenue, up by 11.10 percentage points[6]. - Research and development expenses increased to ¥17,260,292.96 in Q1 2024, up from ¥14,269,124.81 in Q1 2023, indicating a focus on innovation[24]. - Research and development expenses for Q1 2024 were CNY 7,133,660.40, an increase of 18.1% compared to CNY 6,039,616.74 in Q1 2023[33]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,687[12]. - The company reported that QM5 LIMITED holds 40,955,470 shares, representing 16.48% of total shares outstanding[13]. - Xu Nong holds 28,514,417 shares, accounting for 11.48% of total shares[13]. - Michael Mingyan Liu owns 25,284,935 shares, which is 10.18% of total shares[13]. - David Fan holds 17,379,262 shares, representing 6.99% of total shares[13]. Government and Regulatory Matters - The company received government subsidies amounting to ¥951,701.65, which positively impacted its financial results[10]. - The company received approval for its "metal bone needle" from the National Medical Products Administration, which is designed for use in limb fracture fixation[16]. - A notification from the Henan Provincial Medical Security Bureau announced the implementation of bulk procurement for orthopedic trauma medical consumables starting May 10, 2024[16]. - The bulk procurement cycle for orthopedic trauma consumables will last for two years, while the ultrasound knife head procurement will last for one year[16]. Strategic Investments - The company plans to invest €5 million in Implanet through its wholly-owned subsidiary, increasing its shareholding from 41.03% to 74.56%[17]. - The company completed the registration of its capital change in February 2024, with Implanet now included in the consolidated financial statements[18]. - The company has appointed five board members for Implanet, including its chairman and CEO, indicating a strategic move to strengthen governance[17]. Operational Costs - Total operating costs for Q1 2024 were ¥89,364,386.84, down 26.0% from ¥120,889,749.74 in Q1 2023[24]. - The company reported a significant increase in management expenses to ¥12,059,522.88 in Q1 2024, compared to ¥7,678,887.23 in Q1 2023[24]. - The company paid 34,097,832.62 RMB for goods and services in Q1 2024, an increase from 22,593,863.65 RMB in Q1 2023[36].

证券代码：688085 证券简称：三友医疗 公告编号：2024-012 上海三友医疗器械股份有限公司 2023 年度募集资金存放与使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 （一） 实际募集资金金额和资金到账时间 经上海证券交易所科创板上市委员会 2020 年 1 月 8 日审核同意，并经中国 证券监督管理委员会于 2020 年 3 月 12 日《关于同意上海三友医疗器械股份有限 公司首次公开发行股票注册的批复》（证监许可〔2020〕402 号），公司获准向 社会公开发行人民币普通股 51,333,500 股，每股面值人民币 1.00 元，每股发行 价为人民币 20.96 元，合计募集资金人民币 1,075,950,160.00 元，扣除各项发 行费用（不含税）人民币 97,892,778.72 元后，募集资金净额为 978,057,381.28 元。上述募集资金已全部到位，并由立信会计师事务所（特殊普通合伙）验证并 出具"信会师报字[2020]第 ZA10508 号"验资报 ...

一、监事会会议召开情况 上海三友医疗器械股份有限公司（以下简称"三友医疗"或"公司"）第三 届监事会第七次会议于 2024 年 4 月 24 日以现场方式召开。本次会议的通知于 2024 年 4 月 12 日通过邮件方式送达全体监事。会议应出席监事 3 人，实际到 会监事 3 人，会议由监事会主席马宇立先生主持，本次监事会会议的召集和召 开程序符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规 定，会议决议合法、有效。 二、监事会会议审议情况 证券代码：688085 证券简称：三友医疗 公告编号：2024-018 上海三友医疗器械股份有限公司 第三届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （一）审议通过《2023 年年度报告及其摘要》 议案内容：详见公司同日刊载于上海证券交易所网站（www.sse.com.cn） 的《2023 年年度报告》及《2023 年年度报告摘要》。 表决情况：同意 3 票，弃权 0 票，反对 0 票。 本议案尚需提交公司股东大会审议。 （二）审议通过《2 ...

证券代码：688085 证券简称：三友医疗 公告编号：2024-011 上海三友医疗器械股份有限公司 第三届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海三友医疗器械股份有限公司（以下简称"三友医疗"或"公司"）第三 届董事会第十次会议于 2024 年 4 月 24 日以现场结合通讯方式召开。本次会议 的通知于 2024 年 4 月 12 日通过邮件方式送达全体董事。会议应出席董事 9 人， 实际到会董事 9 人，会议由董事长 Michael Mingyan Liu（刘明岩）先生主持， 本次会议的召集和召开程序符合有关法律、行政法规、部门规章、规范性文件 和《公司章程》的规定，会议决议合法、有效。 二、董事会会议审议情况 （一）审议通过《2023 年年度报告及其摘要》 议案内容：详见公司同日刊载于上海证券交易所网站（www.sse.com.cn） 的《2023 年年度报告》及《2023 年年度报告摘要》。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案已 ...

公司代码：688085 公司简称：三友医疗 上海三友医疗器械股份有限公司 2023 年度内部控制评价报告 上海三友医疗器械股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称"公司"）内部控制制度和评价办法，在内部控制日常监督和专 项监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评 价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于 ...

上海三友医疗器械股份有限公司 审计委员会 2023年度履职情况报告 根据《上海证券交易所科创板上市公司自律监管指引第 1 号一规范运作》、 《上市公司治理准则》、《上海证券交易所科创板股票上市规则》、《公司章程》 和《上海三友医疗器械股份有限公司董事会审计委员会实施细则》的有关规定, 上海三友医疗器械股份有限公司(以下简称"公司")董事会审计委员会积极 开展工作,认真履行职责。现就2023年度工作情况向董事会作如下报告: 一、审计委员会构成 公司第三届董事会审计委员会成员为独立董事李莫愁女士、独立董事顾绍 字女士、董事郑晓裔女士,主任委员由李莫愁女士担任。 报告期内,宋瑞先生于 2023年 2月因个人原因辞去公司第三届董事会独立 董事及审计委员会委员、提名委员会主任委员职务。公司第三届董事会提名委 员会第一次会议同意补选顾绍宇女士为公司第三届董事会独立董事候选人,经 第三届董事会第四次会议及 2023年第一次临时股东大会审议,同意顾绍宇女士 担任第三届董事会独立董事及审计委员会委员、提名委员会主任委员职务。本 人认为聘任程序严格按照法律法规的规定,顾绍宇女士符合《上市公司独立董 事管理办法》等法律法规中对于董 ...